What is the global market size of Asia Pacific Stem Cell Market?

Asia Pacific Stem Cell Market size was valued at USD 2.03 billion in 2021 and is poised to grow from USD 2.21 billion in 2022 to USD 4.45 billion by 2030, at a CAGR of 9.1% during the forecast period (2023-2030).

Asia Pacific Stem Cell Companies

Asia Pacific Stem Cell Market Competitive Landscape

Asia Pacific Stem Cell Market Top Player’s Company Profile

Fujifilm Holdings Corporation (Japan)

Mesoblast Limited (Australia)

Hitachi, Ltd. (Japan)

Thermo Fisher Scientific Inc. (US)

Beckman Coulter, Inc. (US)

Lonza Group Ltd. (Switzerland)

Celgene Corporation (US)

STEMCELL Technologies Inc. (Canada)

Takara Bio Inc. (Japan)

Medipost Co., Ltd. (South Korea)

Cell Biotech Co., Ltd. (South Korea)

Roche Holding AG (Switzerland)

Takeda Pharmaceutical Company Limited (Japan)

Daiichi Sankyo Company, Limited (Japan)

Sysmex Corporation (Japan)

Sumitomo Dainippon Pharma Co., Ltd. (Japan)

Wuxi AppTec Co., Ltd. (China)

Japan Tissue Engineering Co., Ltd. (Japan)

Kaken Pharmaceutical Co., Ltd. (Japan)

Regeneus Ltd. (Australia)

Asia Pacific Stem Cell Market

FAQs

Asia Pacific Stem Cell Market size was valued at USD 2.21 billion in 2022 and is poised to grow from USD 2.41 billion in 2023 to 4.84 USD billion by 2031, at a CAGR of 9.1% during the forecast period (2024-2031)

The Asia-Pacific stem cell market is characterized by the presence of a diverse range of players, including both regional and international companies. Several prominent companies have established their dominance in the market, leveraging their expertise in stem cell research, clinical applications, and technological advancements. These key players focus on strategic collaborations, partnerships, and mergers and acquisitions to expand their product portfolios, strengthen their market presence, and gain a competitive edge. Additionally, they invest significantly in research and development activities to drive innovation and develop novel stem cell therapies. Some of the leading companies operating in the Asia-Pacific stem cell market constantly strive to enhance their product offerings, expand their geographical reach, and maintain a strong foothold in the dynamic and evolving stem cell market of the Asia-Pacific region. 'Fujifilm Holdings Corporation (Japan)', 'Mesoblast Limited (Australia)', 'Hitachi, Ltd. (Japan)', 'Thermo Fisher Scientific Inc. (US)', 'Beckman Coulter, Inc. (US)', 'Lonza Group Ltd. (Switzerland)', 'Celgene Corporation (US)', 'STEMCELL Technologies Inc. (Canada)', 'Takara Bio Inc. (Japan)', 'Medipost Co., Ltd. (South Korea)', 'Cell Biotech Co., Ltd. (South Korea)', 'Roche Holding AG (Switzerland)', 'Takeda Pharmaceutical Company Limited (Japan)', 'Daiichi Sankyo Company, Limited (Japan)', 'Sysmex Corporation (Japan)', 'Sumitomo Dainippon Pharma Co., Ltd. (Japan)', 'Wuxi AppTec Co., Ltd. (China)', 'Japan Tissue Engineering Co., Ltd. (Japan)', 'Kaken Pharmaceutical Co., Ltd. (Japan)', 'Regeneus Ltd. (Australia)'

Governments in the Asia-Pacific region have been actively supporting and promoting stem cell research and therapies. They have established favorable regulatory frameworks, allocated funding for research and development, and facilitated collaborations between academic institutions, hospitals, and industry players. For instance, in Japan, the government has implemented the Regenerative Medicine Promotion Act, providing a pathway for accelerated approval of regenerative medicine products, including stem cell therapies. Such initiatives encourage innovation, attract investments, and drive the growth of the stem cell market.

Emergence of Off-the-Shelf Stem Cell Products: Another trend in the Asia-Pacific stem cell market is the emergence of off-the-shelf stem cell products. Efforts are being made to develop standardized, quality-controlled stem cell products that can be readily available for clinical use without the need for individualized cell production. This trend aims to overcome challenges associated with scalability, cost, and logistics in personalized cell therapies. For example, South Korean companies are actively working on developing allogeneic stem cell products for various therapeutic applications, including orthopedics and dermatology. The availability of off-the-shelf stem cell products has the potential to streamline treatment procedures, expand accessibility, and drive market growth.

China dominated the Asia Pacific stem cell market, while India stands out as the fastest-growing region, showcasing remarkable potential and attracting significant attention from investors and healthcare stakeholders.

Feedback From Our Clients

"We have purchased recently a report from SkyQuest Technology, and we are happy to inform you that this report was so useful and practical for our team. Skyquest Team was very active and our queries were followed up completely.It was amazing. "

- Mr. Ali Zali, Commercial Director, ICIIC Iran.

Asia Pacific Stem Cell Market Competitive Landscape

Asia Pacific Stem Cell Market Report Snapshots

Want to customize this report?

FAQs

Request Free Customization

Feedback From Our Clients

$3,500

Asia Pacific Stem Cell Market Competitive Landscape

Asia Pacific Stem Cell Market Report Snapshots

Want to customize this report?

FAQs

What is the global market size of Asia Pacific Stem Cell Market?

Who are the key vendors in the Asia Pacific Stem Cell Market?

What is the key driver of Asia Pacific Stem Cell Market?

What is the key market trend for Asia Pacific Stem Cell Market?

Which region accounted for the largest share in Asia Pacific Stem Cell Market?

Request Free Customization

Related Reports

Feedback From Our Clients

$3,500